Shots:
- The P-IV HER-MES study evaluates the tolerability & efficacy of Aimovig (70/140mg) vs topiramate in 777 patients with episodic or chronic migraine (≥4 migraine days/month) prior to not being treated with migraine prevention treatment or previously failed up to 3 previous therapies. The study was conducted in collaboration with Novartis at 82 study sites in Germany
- The results showed a lower discontinuation rate due to AEs (10.6% vs 38.9%). Additionally, a greater proportion of patients achieved at least a 50% reduction from baseline in their MMDs (55.4% vs 31.2%)
- Aimovig is the 1st FDA-approved migraine preventive treatment that targets CGRP receptors associated with migraine
Click here to read the full press release/ article | Ref: PR Newswire | Image: Wall Street Journal
The post Amgen Reports Results of Aimovig (erenumab-aooe) in P-lV Study for the Treatment of Episodic and Chronic Migraine first appeared on PharmaShots.
